Everyone is happy when a person can get out of the hospital a day earlier than planned. This is particularly important when patients have severe cases of COVID-19.
Study Results Released This Week
This week, the results of an Eli Lilly study sponsored by the United States National Institute of Allergy and Infectious Diseases was made public. Note: this study has not been peer-reviewed or released to the public.
This study included one thousand patients suffering from COVID-19. Remdesivir is being used to treat severe symptoms of COVID-19 and results in patients leaving the hospital by up to four days earlier than without this drug.
A rheumatoid arthritis drug, baricitinib (Olumiant – https://wb.md/3huzdI2) was given to seriously ill patients already being treated with remdesivir (https://bit.ly/3bZdBCw). The results show that the patients treated with both remdesivir and baricitinib left the hospital one day earlier than those using remdesivir exclusively.
Why Does it Work?
Baricitinib acts to tamper the immune response. Many patients with severe symptoms from COVID-19 experience an overactive immune system that can exacerbate symptoms from serious to near-deadly.
The United States Food and Drug Administration has not been involved to date in this study. The results open the door to begin more definitive clinical testing to offer another arrow in the quiver of options to treat seriously ill COVID-19 patients.
There are probably many drugs that can be used to reduce the symptoms and hospitalization days associated with COVID-19. This is another of over a dozen that have been brought to the forefront in the past three or four months. It cannot be given full permission to use, but it can gain emergency use authorization from the FDA for temporary testing.
Live Longer & Enjoy Life! – Red O’Laughlin – RedOLaughlin.com